<DOC>
	<DOCNO>NCT01730040</DOCNO>
	<brief_summary>This randomize , double-blind , active-comparator , parallel-group study patient high cardiovascular risk nonfamilial hypercholesterolemia heterozygous familial hypercholesterolemia ( heFH ) .</brief_summary>
	<brief_title>Study Efficacy Safety Alirocumab ( REGN727/SAR236553 ) Combination With Other Lipid-modifying Treatment ( LMT ) ( ODYSSEY OPTIONS I )</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Patients screen ( visit 1 ) LDLC great equal 70 mg/dL document CVD , adequately control daily dose atorvastatin . OR 2 . Patients screen ( visit 1 ) LDLC great equal 100 mg/dL high risk CVD adequately control daily dose atorvastatin . 1 . LDLC great 250 mg/dL 2 . LDLC le 70 mg/dL screen visit patient history document CVD 3 . LDLC le 100 mg/dL screen visit patient without history document CHD nonCHD CVD , risk factor 4 . TG great 400 mg/dL 5 . Homozygous FH ( clinically previous genotyping ) 6 . Currently take statin atorvastatin 7 . Currently take Ezetimibe ( EZE ) 8 . Not stable dose allowable lipid modifying treatment ( LMT ) ( The inclusion/ exclusion criterion provide intend contain consideration relevant patient 's potential participation clinical trial ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>